09:06 AM EST, 11/12/2024 (MT Newswires) -- Bicara Therapeutics ( BCAX ) reported a Q3 net loss Tuesday of $1.60 per share, narrowing from a loss of $38.23 a year earlier.

A single analyst polled by Capital IQ expected a loss of $0.43 per share.

As of Sept. 30, the company said it had $520.8 million as cash and cash equivalents, that are expected to fund its operations through H1 2029.

Bicara Therapeutics ( BCAX ) closed its initial public offering in September.